JAKAVI demonstrated superior results to best available therapy1
Significantly more patients receiving JAKAVI met the primary composite endpoint compared with those receiving BAT1,2
Primary response at Week 321-3

Haematocrit control was defined as the absence of phlebotomy eligibility from Week 8 to Week 32, with no more than one post-randomisation phlebotomy allowed prior to Week 8. Phlebotomy eligibility was defined as haematocrit >45% and ≥3% higher than the baseline or >48%, whichever was lower.1,2 Spleen response was defined as ≥35% reduction from baseline in spleen volume, as assessed by MRI or CT.1,2
- Among patients who achieved a primary response, 91% had a durable response at Week 481,2
- Durability of primary response at Week 48 was a key secondary endpoint1,2
77% of patients receiving JAKAVI met at least one component of the primary endpoint1,2